NCT00361244终止1 期
A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 6
- 主要终点
- To determine the maximum tolerated dose of SU011248 when given in combination with irinotecan and cetuximab in patients with previously treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma
研究概览
简要总结
The purpose of this study is to determine the safety of SU011248 and the highest dose of this drug that can be given safely in combination with the chemotherapy drugs irinotecan and cetuximab. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further. Other studies have demonstrated the possibility that SU011248 may enhance the anti-tumor activity of other chemotherapy drugs such as irinotecan and cetuximab.
详细描述
- Participants will be given a supply of SU011248 capsules to take at home in the morning for two weeks. After taking the capsules for two weeks, there will be a one-week rest period.
- Irinotecan will be administered on days 1 and 8 of every 21-day cycle as an intravenous infusion over 90 minutes. Cetuximab will be administered intravenously on days 1, 8 and 15 of every 21-day cycle. The first treatment of cetuximab is a larger dose. Beginning with the second treatment, the participant will receive a smaller dose of cetuximab.
- Blood work will be repeated at every clinic visit on days 1 and 8. During cycle 1, blood will also be drawn on day 15.
- Tumor assessments will be repeated after 6 weeks, 12 weeks, and every 9 weeks thereafter, and will be assessed by both a CT scan of the abdomen, pelvis, and a chest x-ray. MUGA scans will be repeated every 4 cycles (12 weeks).
- Participants may continue to receive cycles of study treatment as long as their disease does not progress and they do not experience any serious side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic proof of adenocarcinoma of the colon or rectum with evidence of metastatic disease. The site of the primary lesion must be or have been confirmed endoscopically, radiologically, or surgically to be or have been in the large bowel
- •Patients must have received one (and only one) prior chemotherapy regimen for metastatic disease using 5-FU/LV or Xeloda in combination with oxaliplatin and Avastin.
- •> 4 weeks must have elapsed from the time of major surgery
- •> 2 weeks must have elapsed from the time of minor surgery
- •> 4 weeks must have elapsed from the time of major radiotherapy
- •Normal organ and marrow function
- •Measurable disease be RECIST criteria
- •Older than 18 years of age
- •ECOG performance status of 0-1
- •Life expectancy > 12 weeks
排除标准
- •Previous treatment with irinotecan, cetuximab or SU011248
- •Any of the following within the 12 months prior to study drug administration: severe/unstable angina; myocardial infarction; symptomatic congestive heart failure; cerebrovascular accident; or transient ischemic attack.
- •Known brain metastases or carcinomatous meningitis
- •Uncontrolled serious medical or psychiatric illness
- •NCI CTCAE grade 3 or greater hemorrhage within 4 weeks of starting study treatment
- •Uncontrolled hypertension
- •Diagnosis of any secondary malignancies with the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, localized prostate cancer with a normal PSA within the past 3 months, in situ bladder cancer, or in situ cervical cancer
- •Pregnant or breastfeeding
- •Concurrent treatment on another clinical trial
结局指标
主要结局
To determine the maximum tolerated dose of SU011248 when given in combination with irinotecan and cetuximab in patients with previously treated locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma
时间窗: 1 year
To determine the response rate of SU011248 when given in combination with irinotecan and cetuximab in this patient population.
次要结局
- to assess overall survival, progression-free survival, time to progression and duration of response.
- To evaluate the toxicities of this combination of drugs in this patient population(1 year)
研究者
Andrew X. Zhu, MD
Physician Hematology/Oncology
Massachusetts General Hospital
研究点 (6)
Loading locations...
相似试验
已完成
1 期
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced CancerAdvanced Solid TumorsNon Small Cell Lung CancerNCT00712504Pfizer49
已完成
1 期
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered TogetherSolid TumorsNeoplasmsBreast CancerNCT00618124Pfizer77
已完成
1 期
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid TumorsNeoplasmsNCT00528619Pfizer96
已完成
1 期
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 YearsAcute Myeloid LeukemiaNCT00783653Universitätsklinikum Hamburg-Eppendorf22
已完成
1 期
Study Of Sunitinib Plus FOLFOX In Patients With Solid TumorsNeoplasmsColorectal NeoplasmsNCT00599924Pfizer53